The Value of Ischemic Cardiac Biomarkers to Predict Spontaneous Breathing Trial or Extubation Failure: A Systematic Review
Open Access
- 30 May 2024
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (11) , 3242
Abstract
Background: It is unclear whether other cardiac biomarkers than NT-proBNP can be useful in the risk stratification of patients weaning from mechanical ventilation. The aim of this study is to summarize the role of ischemic cardiac biomarkers in predicting spontaneous breathing trial (SBT) or extubation failure. Methods: We systematically searched Embase, MEDLINE, Web of Science, and Cochrane Central for studies published before January 2024 that reported the association between ischemic cardiac biomarkers and SBT or extubation failure. Data were extracted using a standardized form and methodological assessment was performed using the QUIPS tool. Results: Seven observational studies investigating four ischemic cardiac biomarkers (Troponin-T, Troponin-I, CK-MB, Myoglobin) were included. One study reported a higher peak Troponin-I in patients with extubation failure compared to extubation success (50 ng/L [IQR, 20–215] versus 30 ng/L [IQR, 10–86], p = 0.01). A second study found that Troponin-I measured before the SBT was higher in patients with SBT failure in comparison to patients with SBT success (100 ± 80 ng/L versus 70 ± 130 ng/L, p = 0.03). A third study reported a higher CK-MB measured at the end of the SBT in patients with weaning failure (SBT or extubation failure) in comparison to weaning success (8.77 ± 20.5 ng/mL versus 1.52 ± 1.42 ng/mL, p = 0.047). Troponin-T and Myoglobin as well as Troponin-I and CK-MB measured at other time points were not found to be related to SBT or extubation failure. However, most studies were underpowered and with high risk of bias. Conclusions: The association with SBT or extubation failure is limited for Troponin-I and CK-MB and appears absent for Troponin-T and Myoglobin, but available studies are hampered by significant methodological drawbacks. To more definitively determine the role of ischemic cardiac biomarkers, future studies should prioritize larger sample sizes, including patients at risk of cardiac disease, using stringent SBTs and structured timing of laboratory measurements before and after SBT.Keywords
Funding Information
- Roche Diagnostics Ltd. (Bazel, Switzerland) (9110193179)
This publication has 49 references indexed in Scilit:
- Serial Assessment of Myocardial Injury Markers in Mechanically Ventilated Patients With SARS-CoV-2 (from the Prospective MaastrICCht Cohort)The American Journal of Cardiology, 2022
- Cardiac biomarkers, cardiac injury, and comorbidities associated with severe illness and mortality in coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysisImmunity, Inflammation and Disease, 2021
- Meta-analysis of cardiac markers for predictive factors on severity and mortality of COVID-19International Journal of Infectious Diseases, 2021
- Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019JAMA Cardiology, 2020
- Predictors of mortality in hospitalized COVID‐19 patients: A systematic review and meta‐analysisJournal of Medical Virology, 2020
- Effect of Pressure Support vs T-Piece Ventilation Strategies During Spontaneous Breathing Trials on Successful Extubation Among Patients Receiving Mechanical VentilationJAMA, 2019
- The Interleukin-33/ST2 Pathway Is Expressed in the Failing Human Heart and Associated with Pro-fibrotic Remodeling of the MyocardiumJournal of Cardiovascular Translational Research, 2017
- Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohortInternational Journal of Cardiology, 2015
- Weaning-induced cardiac dysfunction: where are we today?Intensive Care Medicine, 2014
- Prevalence of myocardial ischemia during mechanical ventilation and weaning and its effects on weaning successHeart & Lung, 2006